This page shows the latest Capital investment news and features for those working in and with pharma, biotech and healthcare.
As part of a new agreement, European private equity firm, Astorg and middle-market private equity investment firm, Amulet Capital Partners, have announced that Astorg will acquire OPEN Health, a global ... OPEN Health was built around Amulet’s
We still need clarity on how the government will fund institutions like the MHRA and NICE, but the measures to boost investment in science and research in the UK announced by ... This funding is part of a wider £5.9bn capital investment in the UK’s
The SPAC is sponsored by Foresite Capital, a healthcare and life sciences investment firm based in the US. ... Most of the money raised will come from the SPAC itself, with approximately $75m to be raised through a private round with backers including
The DiD acquisition is Lucid Group’s first with backing from its new investment partner Intermediate Capital Group (ICG), previously announced in March.
Cidron Aida Bidco, a subsidiary of private equity investor Nordic Capital, has completed its acquisition of speciality pharma company ADVANZ PHARMA. ... Nordic Capital will be pivotal in helping the business through both its deep sector expertise and
It received seed funding from Mission BioCapital, which was joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures and
More from news
Approximately 2 fully matching, plus 57 partially matching documents found.
High-profile disinvestments include those by Pfizer and Eli Lilly. However, Pfizer has since announced that, together with investment firm Bain Capital, it has created a new drug company called Cerevel ... Regulatory processes in Mainland China have
This include specialist venture capital firms, which are upping their investment in the region, which is seen as underdeveloped compared to the sometime overheated Massachusetts and California biotech markets. ... As venture capital (VC) investors,
to encourage a home-grown pharma industry, as well as investment from multinational giant. ... Money flowing into Europe. Meanwhile, just as multinationals are increasing their investments in China, there is also a huge amount of investment capital
The greater risk - given the inelasticity of the supply of R&D to the sudden increase in capital - is a lowering of the quality bar as marginal companies obtain investment. ... Keeping the bar high. To guard against this risk, it is essential that
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Will head up the former Teva portoflio CVC Capital Partners recently acquired. ... London-based investment firm CVC Capital Partners has appointed Anish Mehta as chief executive officer of the international women’s health assets portfolio it acquired
Sanofi.”. His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.
has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates. ... Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity
Samuels also brings considerable business and operational experience to the position, with a particular expertise in economics, capital markets and investment decision-making. ... He currently serves as a director at Perrigo Company and Stamps.com, and
Dr Hoffman brings 30 years of experience in the pharmaceutical and financial industries to the biotech, currently serving as a senior advisor to PDL BioPharma and president of 10x Capital, an ... investment management firm.
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
The Partners at GHO Capital said: “The investment in Genesis Research follows years of work internally to identify market leading platforms with ambitious management teams in RWE and HEOR. ... About GHO Capital. Global Healthcare Opportunities, or GHO
MAT is excited to officially announce a minority investment from Silversmith Capital Partners. ... that drive decision-making across the product lifecycle, today announced a $30 million minority investment from Silversmith Capital Partners, a
This is Lucid Group’s first acquisition backed by its new investment partner Intermediate Capital Group (ICG) – a leading global alternative asset manager.
Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone. ... ICG brings deep healthcare sector expertise, a global
Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models. ... The funding comes from two existing backers. Mercia has invested from its Northern Venture Capital Trust (VCT) and Enterprise Investment Scheme (EIS)
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...